Scinai Immunotherapeutics Ltd. (SCNI)
SCNI Stock Price Chart
Explore Scinai Immunotherapeutics Ltd. interactive price chart. Choose custom timeframes to analyze SCNI price movements and trends.
SCNI Company Profile
Discover essential business fundamentals and corporate details for Scinai Immunotherapeutics Ltd. (SCNI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 May 2015
Employees
31.00
Website
https://www.scinai.comCEO
Amir Reichman
Description
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
SCNI Financial Timeline
Browse a chronological timeline of Scinai Immunotherapeutics Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 20 Aug 2026
Earnings released on 7 Jul 2026
Earnings released on 10 Jun 2026
EPS came in at $0.94 , while revenue for the quarter reached $487.67k .
Earnings released on 2 Nov 2025
EPS came in at -$3.57 , while revenue for the quarter reached $277.29k .
Earnings released on 2 Sept 2025
EPS came in at -$1.20 , while revenue for the quarter reached $386.50k .
Earnings released on 7 May 2025
EPS came in at -$10.40 , while revenue for the quarter reached $386.50k .
Earnings released on 22 Nov 2024
EPS came in at $8.40 , while revenue for the quarter reached $168.00k .
Earnings released on 15 Aug 2024
EPS came in at -$3.57 , while revenue for the quarter reached $284.00k .
Earnings released on 2 Jul 2024
EPS came in at -$4.00 surpassing the estimated -$6.20 by +35.48%.
Stock split effective on 21 May 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Oct 2023
EPS came in at -$6.60 surpassing the estimated -$9.40 by +29.79%.
Earnings released on 11 Aug 2023
EPS came in at -$1.11 falling short of the estimated -$0.91 by -21.98%.
Earnings released on 15 May 2023
EPS came in at -$5.45 surpassing the estimated -$22.00 by +75.23%.
Earnings released on 30 Nov 2022
EPS came in at $0.03 surpassing the estimated -$1.00 by +102.90%.
Stock split effective on 25 Nov 2022
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Aug 2022
EPS came in at -$0.61 surpassing the estimated -$1.00 by +38.84%.
Earnings released on 1 Jun 2022
EPS came in at -$0.50 .
SCNI Stock Performance
Access detailed SCNI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
